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PAR-2 and we demonstrate that matriptase-dependent enhancement of
collagenolysis from OA cartilage is blocked by PAR-2 inhibition.
Conclusions: This study assessed for the ﬁrst time the role of the
transmembrane serine protease matriptase in cartilage destruction in OA.
Elevated matriptase expression in OA, its ability to activate selective
proMMPs as well as induce collagenase expression make this serine pro-
teinase a key initiator and inducer of cartilage destruction in OA. We
propose that the indirect effects of matriptase are PAR-2-mediated and a
more detailed understanding of these mechanisms may highlight important
new therapeutic targets for OA treatment.
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Purpose: Chondrocytes express the calcium binding proteins S100A8 and
S100A9, and both are increased in cartilage in acute and chronic inﬂam-
matory arthritis; however their role in osteoarthritis (OA) is less clear. We
recently demonstrated that chondrocyte S100a8 and S100a9 mRNA were
co-ordinately increased during the onset of experimental OA, but both were
signiﬁcantly down-regulated as OA progressed, although asynchronously
with S100a9 > S100a8. S100A8 and S100A9, but not the heterodimer
(S100A8/S100A9) decrease aggrecan and collagen-2 and induce MMP
and ADAMTS expression in isolated primary articular chondrocytes. The
aim of this study is to determine if similar effect(s) are seen using a
more physiologically-relevant explant culture system and whether MMPs
implicated in late stage cartilage breakdown in OA are activated.
Methods: Ovine articular cartilage explants were cultured for 4 days
in serum-free media ± 10-7M or 10-8M human S100A8, S100A9 or
S100A8/S100A9 (n=3/treatment). Gene expression of S100a8, S100a9, key
cartilage proteins, metalloproteinases and their inhibitors was measured
using real time RT-PCR. Collagen and aggrecan release were measured
as hydroxyproline and glycosaminoglycan (GAG) respectively. Activity of
MMP-2 and MMP-9 were evaluated by gelatin zymography, and MMP-13
using a ﬂuorometric assay.
Results: Aggrecan and collagen-2 expression were not regulated by S100A8
or S100A9. Adamts-1, Adamts-5, Mmp-1, and Mmp-3 mRNA levels were
dose-dependently up-regulated by S100A8 (p<0.01) and S100A9 (p<0.05)
while no change was seen in Mmp-2, Mmp-9, Mmp-14, Timp-1, Timp-2
or Timp-3 mRNA levels. The heterodimer did not regulate expression
of any genes other than Mmp-13. Mmp-13 was increased by S100A8
(≈100 fold; p<0.05) and S100A9 (≈20 fold; p=0.8), but down-regulated
by S100A8/S100A9 (≈25 fold; p<0.05). S100a9 expression was dose-
dependently up-regulated by S100A8 (p<0.01) and S100A9 (p<0.04).
S100a8 expression was low but increased in response to 10-7M S100A8.
There was no collagen release in any cultures. Only in response to 10-7M
S100A8 we observed: increased GAG release (3-fold); activation of pro-
MMP-2; secretion of pro-MMP-9 and pro-MMP-13 (no active MMP-9 or
MMP-13 were detected in any cultures).
Conclusions: These results have conﬁrmed that both S100A8 and S100A9
homodimers are implicated in chondrocyte-mediated cartilage degradation
by increasing expression of MMPs and ADAMTS. Over the short time course
of these experiments S100A8 was more pro-catabolic than S100A9, leading
to greater up-regulation of metalloproteinase mRNA, release of pro-MMP-9
and pro-MMP-13, release and activation of MMP-2, and cartilage aggrecan
loss. Longer-term cultures will determine whether these differences are
maintained and if MMP-driven collagenolysis ultimately occurs. Chondro-
cyte S100a9 and S100a8 expression has been shown to be increased by
IL-1, and the current data also suggests some degree of auto-regulation.
Changes in cartilage explant gene expression by S100A8 and S100A9 largely
matched those in isolated chondrocytes except that in the latter aggrecan
and collagen-2 were signiﬁcantly down-regulated by both homodimers.
Of particular interest was the opposite effect on Mmp-13 expression of
both homodimers versus the heterodimer, implicating the uncoordinated
regulation of the two S100 proteins in cartilage degradation.
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Purpose: Aggrecan, a structural extracellular matrix protein, is degraded
by proteolysis in joint injuries and in arthritis as an early key event. We
here investigate the possible role of calpain digestion of human aggrecan,
looking at the preferred order of cleavage and analyzing the in vivo content
of calpain generated aggrecan fragments in knee cartilage and synovial
ﬂuid.
Methods: Human aggrecan fragments were puriﬁed by dissociative and as-
sociative CsCl density gradient centrifugations from: OA-pool (adults, n=10)
and normal (youth, n=1) knee cartilage, and from OA-pool (n=47) and acute
inﬂammatory arthritis (n=2) synovial ﬂuid (SF). Cartilage A1D1 fractions
were in vitro digested by m-calpain (EC nr 3.4.22.17; Calbiochem) for
up to 2h. Aggrecan samples were deglycosylated, separated by SDS-PAGE,
transferred to PVDF membranes and probed with antibodies against calpain
generated neo-epitopes (PGVA, GDLS, and EDLS) or against aggrecan G1-
and G3-domains. N- and C-terminal ends not veriﬁed by immunodetection
were estimated using a calculation model.
Results: To study calpain digestion of aggrecan we produced neoepitope
antibodies against the following human aggrecan calpain sites: -PGVA709,
in the keratan sulfate (KS) domain; -GDLS954, 973, 1353, 1431 and -EDLS1411,1472,
in the chondroitin sulfate 1 (CS1) region. Neoepitope speciﬁcity of the
GDLS and PGVA antibodies were conﬁrmed by complete blocking of the
Western blot immunoreactions by the immunogen peptides and by no
blocking using spanning peptides. The EDLS antibody not only recognized
the neoepitope but also the internal sequence. Western blot experiments
of in vitro digested aggrecan (A1D1 from cartilage OA-pool) showed that
calpain cuts human aggrecan in several sites in six separate regions (a–f,
Fig. 1). Time dependent in vitro kinetic studies showed that calpain has a
preferred order of cutting aggrecan, as follows: site-d, -b, -a, -e and site-f.
Due to weak signals it was not possible to get kinetic data on cleavage site-
c. Except that site-a and site-e was exchanged, the same preferred calpain
cleavage order was observed in aggrecan prepared from normal cartilage
as for the OA-pool. Calpain generated aggrecan fragments G1-PGVA (137
kDa), G1-EDLS (310 kDa) and AVPV-GDLS (225 kDa) were also detected in
vivo in OA cartilage, and in similar amounts in normal cartilage. Also, a
ARGS-EDLS (280 kDa) fragment, with an aggrecanase generated N-terminal,
was detected in SF from patients with acute inﬂammatory arthritis but not
in the SF OA-pool.
Figure 1. Six (a–f) calpain cleavage sites/regions were found in human aggrecan. OA car-
tilage (A1D1) was in vitro digested by calpain and fragments were visualized by Western
blot. Illustration of human aggrecan, calpain cleavage sites and calpain in vitro generated
fragments (Mw in kDA).
Conclusions: Our results indicate that calpain cuts human aggrecan in
at least six speciﬁc sites/regions in a preferred order. The results further
suggest that calpain has a function in digesting aggrecan in the CS region
as a step in physiological C-terminal maturation. We can not rule out a role
for calpain digestion of aggrecan also in joint diseases or injuries.
